$Replimune(REPL.US)$ NEWS Replimune Group, Inc. announced positive interim results from the ARTACUS Phase 1/2 clinical trial evaluating RP1 monotherapy for skin cancers in transplant patients, showing a 34.8% overall response rate with good durability. The treatment was well-tolerated and resulted in immune activation.
Despite no recent insider transactions, those over the past year fail to inspire confidence. The modest insider ownership provides reasonable company alignment. Investors are warned of several signs in Replimune Group.
$Oncorus Inc(ONCR.US)$ The reason why I am interested in oncolytic virus is that the virus itself is a kind of drug, and at the same time, the virus can become the carrier of other drugs. This dual property is not possessed by other drugs at present, and it is up to us to fully exploit this function.$Replimune(REPL.US)$$Candel Therapeutics(CADL.US)$
Replimune股票讨论区
NEWS
Replimune Group, Inc. announced positive interim results from the ARTACUS Phase 1/2 clinical trial evaluating RP1 monotherapy for skin cancers in transplant patients, showing a 34.8% overall response rate with good durability. The treatment was well-tolerated and resulted in immune activation.
The reason why I am interested in oncolytic virus is that the virus itself is a kind of drug, and at the same time, the virus can become the carrier of other drugs. This dual property is not possessed by other drugs at present, and it is up to us to fully exploit this function. $Replimune(REPL.US)$ $Candel Therapeutics(CADL.US)$
暂无评论